Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$30.95 USD
+1.11 (3.72%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $30.96 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.95 USD
+1.11 (3.72%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $30.96 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
by Zacks Equity Research
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Brian's Big Idea on Low Priced Stocks
by Brian Bolan
A look at low priced stocks and the Stocks Under $10 Service.
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
by Zacks Equity Research
Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $36.44, moving -0.87% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $34.31, moving +0.7% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $35.92, moving -1.48% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $35.64 in the latest trading session, marking a -1.87% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $43.07, moving -1.76% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $31.04, moving -1.71% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $21.72, marking a +0.14% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $38.47, moving +1.37% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed at $40.17 in the latest trading session, marking a -1.62% move from the prior day.
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $39.08, marking a -0.13% move from the previous day.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $37.65, moving +0.51% from the previous trading session.
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.